Alvotech and Lotus Pharmaceutical are teaming up on plans to commercialize AVT87, a proposed biosimilar to Hemlibra (emicizumab). Lisa Graver, CEO of Alvotech, said in a company press release that the companies "look forward to working together" to broaden access to high-quality biologics.
Alvotech and Lotus Pharmaceutical are teaming up on plans to commercialize AVT87, a proposed biosimilar to Hemlibra (emicizumab).
Lisa Graver, CEO of Alvotech, said in a company press release that the companies "look forward to working together" to broaden access to high-quality biologics.
Hemlibra is an antibody-based therapy approved in the U.S.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Alvotech and Lotus Pharmaceutical are teaming up on plans to commercialize AVT87, a proposed biosimilar to Hemlibra (emicizumab). Lisa Graver, CEO of Alvotech, said in a company press release that the companies "look forward to working together" to broaden access to high-quality biologics. Hemlibra is an antibody-based therapy approved in the U.S.
Hemlibra is an antibody-based therapy approved in the U.S.
Open the app view to save this story, compare related coverage, and continue from the same source.